| Literature DB >> 32494168 |
De-Xian Zhang1, Yao Li1, Xiao-Qing Yang1, Hong-Yu Su1, Qi Wang1, Ze-Hui Zhang1, Yao-Chuan Liu1, Chun-Lian Tian1, Can-Can Cui1, Ming-Chun Liu1.
Abstract
PURPOSE: The aim of this study was to identify the subtype, characterize the antimicrobial resistance, determine the virulence gene distribution, and analyze the biofilm production of Staphylococcus aureus isolates from bovine mastitis milk samples in the Liaoning Province of China.Entities:
Keywords: Staph. aureus; antimicrobial resistance; biofilm formation; mastitic dairy; virulence factors
Year: 2020 PMID: 32494168 PMCID: PMC7234830 DOI: 10.2147/IDR.S247765
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primer Sequences and PCR Conditions Used in This Study
| Primers | Primer Sequence (5ʹ→3ʹ) | Programa | Size of PCR Product (bp) | Reference |
|---|---|---|---|---|
| TAAAGACGATCCTTCGGTGAG | 1 | Variable | Aires-de-Sousa et al 2006 | |
| CAGCAGTAGTGCCGTTTGCTT | ||||
| TTGGAAACGGTTAAAACGAA | 2 | 120 | Park et al, 2011 | |
| GAACCTTCCCATCAAAAACA | ||||
| TCGCATCAAACTGACAAACG | 2 | 478 | Park et al, 2011 | |
| GCAGGTACTCTATAAGTGCC | ||||
| GCATAAAAGCTAGGAATTT | 2 | 257 | Park et al, 2011 | |
| AAATCGGATTAACATTATCC | ||||
| CTAGTTTGGTAATATCTCCT | 2 | 317 | Park et al, 2011 | |
| TAATGCTATATCTTATAGGG | ||||
| AATTATGTGAATGCTCAACCCGATC | 2 | 642 | Park et al, 2011 | |
| AAACTTATATGGAACAAAAGGTACTAGTTC | ||||
| ATGGCAGCATCAGCTTGATA | 2 | 350 | Park et al, 2011 | |
| TTTCCAATAACCACCCGTTT | ||||
| AACTACATCTAGTACTCAACAACAG | 3 | 575 | Tristan et al, 2003 | |
| ATGTGCTTGAATAACACCATCATCT | ||||
| GTCAAGCAGTTATTAACACCAGAC | 3 | 423 | Tristan et al, 2003 | |
| AATCAGTAATTGCACTTTGTCCACTG | ||||
| GTGAAGTTTTAGAAGGTGGAAAGATTAG | 4 | 643 | Tristan et al, 2003 | |
| GCTCTTGTAAGACCATTTTTCTTCAC | ||||
| GTAACAGCTAATGGTCGAATTGATACT | 4 | 524 | Tristan et al, 2003 | |
| CAAGTTCGATAGGAGTACTATGTTC | ||||
| ATTGGCGTGGCTTCAGTGCT | 4 | 292 | Tristan et al, 2003 | |
| CGTTTCTTCCGTAGTTGCATTTG | ||||
| ACATCAGTAATAGTAGGGGGCAAC | 4 | 205 | Tristan et al, 2003 | |
| TTCGCACTGTTTGTGTTTGCAC | ||||
| CTGATTACTATCCAAGAAATTCGATTG | 5 | 209 | Jarraud et al, 2002 | |
| CTTTCCAGCCTACTTTTTTATCAGT | ||||
| GTGCACTTACTGACAATAGTGC | 5 | 309 | Jarraud et al, 2002 | |
| GTTGATGAGTAGCTACCTTCAGT | ||||
| AAGAATTTTTATCTTAATTAAGGAAGGAGTG | 5 | 111 | Jarraud et al, 2002 | |
| TTAGTGAATTTGTTCACTGTGTCGA | ||||
| GTCAYAGAGTCCATAATGCATTTAA | 5 | 535 | Jarraud et al, 2002 | |
| CACCAAATGTATAGCCTAAAGTG | ||||
| GAAGTATCTAATACTTCTTTAGCAGC | 6 | 625 | da Costa et al, 2014 | |
| TCATTTGACAATTCTACACTTCCAAC | ||||
| TGAAAAAGGTTCAAAGTTGATACGAG | 6 | 433 | da Costa et al, 2014 | |
| TGTATTCGATAGCAAAAGCAGTGCA |
Notes: aPCR program. 1: 1×(94ºC, 600s), 30×(94ºC, 20s, 62ºC, 20s, 72ºC, 30s), 1×(72ºC, 600s). 2: 1×(94ºC, 600s), 35×(94ºC, 60s, 55ºC, 60s, 72ºC, 60s), 1×(72ºC, 300s). 3: 1×(94ºC, 600s), 30×(94ºC, 60s, 58ºC, 120s, 72ºC, 60s), 1×(72ºC, 600s). 4: 1×(94ºC, 600s), 30×(94ºC, 60s, 52ºC, 60s, 72ºC, 60s), 1×(72ºC, 600s). 5: 1×(94ºC, 180s), 35×(94ºC, 60s, 60ºC, 60s, 72ºC, 180s), 1×(72ºC, 420s). 6: 1×(94ºC, 180s), 35×(94ºC, 60s, 57ºC, 60s, 72ºC, 180s), 1×(72ºC, 420s).
Dilution Range and Susceptibility Breakpoints of Antimicrobial Agents Used in This Study
| Antimicrobial Agent | Dilution Range (μg/mL) | Susceptibility Break Points (μg/mL) | ||
|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | ||
| Penicillina | 0.03–64 | ≤0.12 | ≥0.25 | |
| Oxacillinb | 0.03–64 | ≤2 | ≥4 | |
| Sulfamethoxazolea | 0.12–128 | ≤64 | ≥128 | |
| Tetracyclinea | 0.03–64 | ≤4 | 8 | ≥16 |
| Enrofloxacina | 0.03–16 | ≤0.25 | 0.5–1 | ≥2 |
| Amoxicillin/clavulanateb | 0.03–64 | ≤2 | 2/4 | ≥8 |
| Cefalexind | 0.03–64 | ≤2 | 4 | ≥8 |
| Ceftiofura | 0.03–64 | ≤24 | 4 | ≥8 |
| Clindamycinb | 0.03–64 | ≤2 | 1–2 | ≥4 |
| Daptomycinc | 0.03–64 | ≤1 | 1–2 | ≥2 |
Notes: aInterpretative breakpoint based on the CLSI breakpoints used in veterinary medicine; binterpretative breakpoint based on the CLSI breakpoints used in human medicine; cinterpretative break point based on EUCAST, 2015;44 dbreakpoint of cefalexin based on cephalothin.
Spa Type and Biofilm Production of the Staph. Aureus Isolates
| Spa Type | Number of Isolates | Biofilm Formation |
|---|---|---|
| t267 | 19 | 1.07±0.16 |
| t730 | 12 | 0.38±0.12 |
| t518 | 8 | 1.02±0.29 |
| t1190 | 6 | 0.67±0.17 |
| t1456 | 5 | 0.46±0.19 |
| t224 | 1 | 1.14±0.37 |
| t9129 | 1 | 0.42±0.15 |
| t177 | 1 | 0.64±0.24 |
Minimum Inhibitory Concentrations (μg/mL) of the Staph. Aureus Isolates from the Milk of Dairy Cows with Mastitis (56 Isolates)
Notes: The dilution ranges tested are those contained within the light blue area, and the concentrations of the different antimicrobial agents are illustrated in the light gray area. The breakpoints were employed according to VET01S, 3rd ed, human, daptomycin was interpreted according to EUCAST, and the breakpoint of cefalexin was based on cephalothin. When available, susceptible and resistance breakpoints are indicated by the vertical green and red line, respectively. The dashed vertical green line represents the breakpoints from humans.
Figure 1Boxplots of the in vitro biofilm production of Staph. aureus strains of the major spa types (n≥5). Each dot represents one strain. Biofilm production was different among the main spa types, especially spa types t730 and t1456, which produced less biofilm than the other main spa type. Significance was determined by an ANOVA test (* P<0.05; ** P<0.01).
Figure 2Confocal laser scanning microscopy of in vitro biofilm production of Staph. aureus isolates. The biofilms were stained with LIVE/DEAD stain. Green represents live cells, red represents dead cells and eDNA, and yellow represents a mixture. (A) SA0007; (B) SA0012; (C) SA0019; (D) SA0020; (E) SA0023; (F) SA0028; (G) SA0031; (H) SA0047; (I) SA0052.